159 related articles for article (PubMed ID: 1678734)
1. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.
Rilke F; Colnaghi MI; Cascinelli N; Andreola S; Baldini MT; Bufalino R; Della Porta G; Ménard S; Pierotti MA; Testori A
Int J Cancer; 1991 Aug; 49(1):44-9. PubMed ID: 1678734
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement.
Bohn U; Aguiar J; Bilbao C; Murias A; Vega V; Chirino R; Díaz-Chico N; Díaz-Chico JC
Int J Cancer; 2002 Oct; 101(6):539-44. PubMed ID: 12237894
[TBL] [Abstract][Full Text] [Related]
3. c-erbB2 expression in correlation to other biological parameters of breast cancer.
Marx D; Schauer A; Reiche C; May A; Ummenhofer L; Reles A; Rauschecker H; Sauer R; Schumacher M
J Cancer Res Clin Oncol; 1990; 116(1):15-20. PubMed ID: 1968902
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
[TBL] [Abstract][Full Text] [Related]
5. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.
Pupa SM; Bufalino R; Invernizzi AM; Andreola S; Rilke F; Lombardi L; Colnaghi MI; Ménard S
J Clin Oncol; 1996 Jan; 14(1):85-94. PubMed ID: 8558226
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
Toikkanen S; Helin H; Isola J; Joensuu H
J Clin Oncol; 1992 Jul; 10(7):1044-8. PubMed ID: 1351537
[TBL] [Abstract][Full Text] [Related]
8. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma.
Bermont L; Algros MP; Baron MH; Adessi GL
Breast Cancer Res Treat; 2000 Sep; 63(2):163-9. PubMed ID: 11097092
[TBL] [Abstract][Full Text] [Related]
9. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
Têtu B; Brisson J
Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490
[TBL] [Abstract][Full Text] [Related]
12. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
13. [Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive].
Zhang G; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():66-74. PubMed ID: 8702314
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome.
Dati C; Muraca R; Tazartes O; Antoniotti S; Perroteau I; Giai M; Cortese P; Sismondi P; Saglio G; De Bortoli M
Int J Cancer; 1991 Apr; 47(6):833-8. PubMed ID: 1672666
[TBL] [Abstract][Full Text] [Related]
16. [Overexpression of c-erbB-2 gene product is associated with poor prognosis factors in breast carcinoma].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):349-53. PubMed ID: 14755939
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
19. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
